FINEARTS-HF provides complementary evidence related to finerenone’s therapeutic effects in previously understudied populations, including those without diabetes (~60% of trial enrollment), those without CKD and those without significant urinary albumin excretion (>60% of the trial with UACR <30 mg g−1). This evidence concerns the gene ALB and diabetes mellitus.